Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even undetectable BCR-ABL1 by Q-RT-PCR does not equate to eradication of the disease. Digital-PCR (dPCR), able to detect 1 BCR-ABL1 positive cell out of 107, has been recently developed. The ISAV study is a multicentre trial aimed at validating dPCR to predict relapses after imatinib discontinuation in CML patients with undetectable Q-RT-PCR. CML patients under imatinib therapy since more than 2 years and with undetectable PCR for at least 18 months were eligible. Patients were monitored by standard Q-RT-PCR for 36 months. Patients losing molecular remission (two consecutive positive Q-RT-PCR with at least 1 BCR-ABL1/ABL1 value above 0.1%) resumed imatinib. The study enrolled 112 patients, with a median follow-up of 21.6 months. Fifty-two of the 108 evaluable patients (48.1%), relapsed; 73.1% relapsed in the first 9 months but 14 late relapses were observed between 10 and 22 months. Among the 56 not-relapsed patients, 40 (37.0% of total) regained Q-RT-PCR positivity but never lost MMR. dPCR results showed a significant negative predictive value ratio of 1.115 [95% CI: 1.013-1.227]. An inverse relationship between patients age and risk of relapse was evident: 95% of patients <45 years relapsed versus 42% in the class ≥45 to <65 years and 33% of patients ≥65 years [P(χ2)<0.0001]. Relapse rates ranged between 100% (<45 years, dPCR+) and 36% (>45 years, dPCR-). Imatinib can be safely discontinued in the setting of continued PCR negativity; age and dPCR results can predict relapse.
Mori, S., Vagge, E., Le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., et al. (2015). Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. AMERICAN JOURNAL OF HEMATOLOGY, 90(10), 910-914 [10.1002/ajh.24120].
|Citazione:||Mori, S., Vagge, E., Le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., et al. (2015). Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. AMERICAN JOURNAL OF HEMATOLOGY, 90(10), 910-914 [10.1002/ajh.24120].|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||Si|
|Titolo:||Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study|
|Autori:||Mori, S; Vagge, E; Le Coutre, P; Abruzzese, E; Martino, B; Pungolino, E; Elena, C; Pierri, I; Assouline, S; D'Emilio, A; Gozzini, A; Giraldo, P; Stagno, F; Iurlo, A; Luciani, M; De Riso, G; Redaelli, S; Kim, D; Pirola, A; Mezzatesta, C; Petroccione, A; Lodolo D'Oria, A; Crivori, P; Piazza, R; Gambacorti Passerini, C|
MORI, SILVIA (Corresponding)
PIAZZA, ROCCO GIOVANNI (Penultimo)
GAMBACORTI PASSERINI, CARLO (Ultimo) (Corresponding)
|Data di pubblicazione:||2015|
|Rivista:||AMERICAN JOURNAL OF HEMATOLOGY|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/ajh.24120|
|Appare nelle tipologie:||01 - Articolo su rivista|